Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-31

@Davisite - I would like to see the imaging data (which was part of the trial but has not been mentioned or disclosed in the trial results) before I had any confidence in the predictive value of the LVAD trial for the CHF Phase 3.

MSB has previously placed great stead in things like ejection fraction (although if you remember they walked that back a little after more results came in). It puzzles me why they haven't released them, as it would lay to rest the doubts in the market about the LVAD trial.

And for those hanging their hat on GI bleeding in that trial - just remember that total hospitalisations were the same for both treated and controls - so no clinical or commercial benefit (unless you can somehow identify in advance those who are going to have a GI bleed and then only treat them) - but that is a whole 'nuther trial from the FDA perspective.